Literature DB >> 11295131

[Polymorphism of MAO-B gene and NAD(P)H: quinone oxidoreductase gene in Parkinson's disease].

M Shao1, Z Liu, E Tao, B Chen.   

Abstract

OBJECTIVE: To investigate whether Parkinson's disease(PD) is associated with genetic polymorphism of intron 13 of monoamine oxidase B(MAO-B) and NAD(P)H: quinone oxidoreductase(NQO1) gene cDNA 609C to T.
METHODS: Association study was performed in 126 PD patients and 136 healthy control subjects matched for age, sex and origin. The NQO1 gene polymorphism was analyzed with the polymerase chain reaction-restriction fragment length polymorphism, the polymorphism of intron 13 of MAO-B was analyzed by allele- specific PCR.
RESULTS: The allelic frequency of the mutant T allele of NQO1 gene was significantly higher in the PD patients as compared to the controls(P<0.05). The relative risk of suffering from PD increased (OR=3.8) in the individuals with T allelic genotype of NQO1 gene, and the odds ratio was as high as 5.7 when the individuals with A or AA genotype of MAO-B gene coexisted with the T allele genotype of NQO1 gene.
CONCLUSION: The cDNA 609T allele of NQO1 gene might be a risk factor of PD, which could be associated with the genetic susceptibility of PD. The high activity A or AA genotype of MAO-B and the low activity genotype of NQO1 gene might have synergistic effect. When both genotypes coexist, the risk of suffering PD will be increased greatly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295131

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi        ISSN: 1003-9406


  8 in total

Review 1.  NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.

Authors:  Albena T Dinkova-Kostova; Paul Talalay
Journal:  Arch Biochem Biophys       Date:  2010-03-31       Impact factor: 4.013

2.  Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression.

Authors:  Almas Siddiqui; Jyothi K Mallajosyula; Anand Rane; Julie K Andersen
Journal:  Neurobiol Dis       Date:  2010-07-21       Impact factor: 5.996

Review 3.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

4.  Quinone reductase 2 is a catechol quinone reductase.

Authors:  Yue Fu; Leonid Buryanovskyy; Zhongtao Zhang
Journal:  J Biol Chem       Date:  2008-06-24       Impact factor: 5.157

5.  Association of NQO1 and TNF polymorphisms with Parkinson's disease: A meta-analysis of 15 genetic association studies.

Authors:  Dongjun Dai; Peipei Lin; Yunliang Wang; Xingyu Zhou; Jianmin Tao; Danjie Jiang; Hanlin Zhou; Ping Ru; Guanghui Pan; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Shiwei Duan
Journal:  Biomed Rep       Date:  2014-06-16

6.  MPP(+)-induced degeneration is potentiated by dicoumarol in cultures of the RCSN-3 dopaminergic cell line. Implications of neuromelanin in oxidative metabolism of dopamine neurotoxicity.

Authors:  R Aguilar Hernández; M J Sánchez De Las Matas; C Arriagada; C Barcia; P Caviedes; M T Herrero; J Segura-Aguilar
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 7.  Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family.

Authors:  Vasilis Vasiliou; David Ross; Daniel W Nebert
Journal:  Hum Genomics       Date:  2006-03       Impact factor: 4.639

8.  The relationship between monoamine oxidase B (MAOB) A644G polymorphism and Parkinson disease risk: a meta-analysis.

Authors:  Ying Liu; Zhiyun Wang; Benshu Zhang
Journal:  Ann Saudi Med       Date:  2014 Jan-Feb       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.